A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies

This study is testing a combination of two cancer treatments to see how well they work together against HER2-expressing cancers that have spread or cannot be removed by surgery. By using two different ways to attack cancer cells, researchers hope to stop the tumors from repairing themselves and help them shrink or stabilize.

This trial is for patients with specific types of advanced cancers where standard treatments haven't worked, or for certain cases of ovarian cancer. Your tumor must test positive for a protein called HER2, and you must meet specific health requirements regarding recent surgeries, radiation, or other medications.

Participants will receive a combination of two medications and will undergo regular monitoring, which includes blood tests, tissue samples, and imaging scans like X-rays or heart ultrasounds. The goal is to find the best dose of these treatments while carefully checking for any side effects.

The study is currently recruiting patients at locations in Phoenix, Arizona, and cities in Florida, including Coral Gables and Deerfield Beach. If you are interested, please check with your doctor to see if one of these centers is a good fit for you.